Share on LinkedInShare on LinkedIn

ARTICLE · 10 MARCH 2026

Spotlight On Upcoming Oral Arguments – March 2026

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

This appeal focuses on Appellant Medtronic Ireland's Article III standing to assert the disputed patents against Appellee Recor following Medtronic Ireland's license agreement with a non-party.

IrelandIntellectual Property

The following arguments will be available live to the public, both in-person and through online audio streaming. Access information will be available by 9 AM ET each day of argument at: https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/.

Tuesday, March 3, 2026, 10:00 A.M.

ReCor Medical, Inc. v. Medtronic Ireland Manufacturing Unlimited Co., No. 2025-1998, Courtroom 402, Panel D.

This appeal focuses on Appellant Medtronic Ireland's Article III standing to assert the disputed patents against Appellee Recor following Medtronic Ireland's license agreement with a non-party. Medtronic Ireland owns U.S. Patent Nos. 8,845,629 and 11,801,085, both related to renal denervation (RDN) systems treating high blood pressure. Recor, a competing RDN system manufacturer, filed a declaratory-judgment action seeking to invalidate the '629 patent. Medtronic Ireland counterclaimed for infringement of both patents. Discovery later revealed that, before asserting

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from